Type 1 diabetes: laboratory follow-up in adults and children
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
At diagnosis, once blood glucose is stable (child and adult)
Laboratory tests
- TSH
- Anti-TPO antibodies (child and adolescent)if neededChild or adolescent: ISPAD recommends TSH, anti-TPO and anti-thyroglobulin antibodies shortly after diagnosis, once the condition is stable [2]; the 2007 HAS ALD guide provided for a search for antithyroid antibodies in the initial tests [3,4]. Positive antibodies prompt closer TSH monitoring [2,5].
- IgA anti-tissue transglutaminase antibodies (tTG-IgA)
- Total IgA (to interpret the serology)
- Lipid profile (child: from age 2)
Do not order
Adult: HbA1c every 3 to 6 months
Laboratory tests
Adult: annual tests
Laboratory tests
- HbA1c
- Serum creatinine with eGFR
- Lipid profile
- TSH
- IgA anti-tissue transglutaminase antibodies (tTG-IgA)if needednon-French guidelineUnexplained weight loss, digestive disorders, malabsorption, osteoporosis, vitamin deficiencies or iron-deficiency anaemia: look for coeliac disease [6,10].
- Total IgAif needednon-French guidelineUnexplained weight loss, digestive disorders, malabsorption, osteoporosis, vitamin deficiencies or iron-deficiency anaemia: look for coeliac disease [6,10].
- Vitamin B12 (if neuropathy or unexplained anaemia)if needednon-French guidelinePeripheral neuropathy or unexplained anaemia: think of pernicious anaemia (Biermer), more frequent in type 1 diabetes [6].
Urine tests
- Urine albumin:creatinine ratio (spot sample)
Child and adolescent: follow-up shared with the paediatric team
Every 3 months
- HbA1c
Once a year
- TSH
- Urine albumin:creatinine ratio (spot sample) (from age 12)if neededFrom age 12 according to NICE [7]; according to ADA, at puberty or from age 11, after 5 years of diabetes [5]; according to ISPAD, at puberty or from age 11, after 2 to 5 years of diabetes, then every year [9]. The 2007 HAS ALD guide provides for yearly albuminuria [4].
- Serum creatinine with eGFR (from puberty or from age 11)if neededISPAD proposes estimating GFR at puberty or from age 11, after 2 to 5 years of diabetes [9]; the 2007 HAS ALD guide provides for yearly serum creatinine [4].
- IgA anti-tissue transglutaminase antibodies (tTG-IgA)if needednon-French guidelineRepeat coeliac disease screening within 2 years of diagnosis, then 5 years later; more often in case of symptoms or an affected first-degree relative [5]; ISPAD: within the year of diagnosis and then every 2 to 5 years [2].
- Total IgA (within 2 years of diagnosis, then every 2 to 5 years)if needednon-French guidelineRepeat coeliac disease screening within 2 years of diagnosis, then 5 years later; more often in case of symptoms or an affected first-degree relative [5]; ISPAD: within the year of diagnosis and then every 2 to 5 years [2].
- Lipid profile (at age 9-11 if the first tests were normal, then every 3 years)if neededIf the initial LDL cholesterol was ≤ 1.00 g/L (2.6 mmol/L): check at age 9-11, then every 3 years [5]; ISPAD also repeats every 3 years if the tests are normal [9]. The 2007 HAS ALD guide provided for a yearly lipid profile [4].
Sources (17)
- Santé publique France. Épidémiologie du diabète de type 1 et de ses complications. Publié le 1er juin 2018, mis à jour le 20 novembre 2019.
- Fröhlich-Reiterer E, Elbarbary NS, Simmons K, Buckingham B, Humayun KN, Johannsen J, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Other complications and associated conditions in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2022;23(8):1451-1467.
- Haute Autorité de santé. Guide affection de longue durée (ALD 8) : diabète de type 1 de l'adulte. Juillet 2007.
- Haute Autorité de santé. Guide affection de longue durée (ALD 8) : diabète de type 1 de l'enfant et de l'adolescent. Juillet 2007.
- American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S297-S320.
- American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S61-S88.
- National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. NICE guideline NG18 (recommandations 1.2.x sur l'HbA1c et 1.2.119 à 1.2.121).
- National Institute for Health and Care Excellence. Coeliac disease: recognition, assessment and management. NICE guideline NG20 (recommandations 1.1 et 1.2).
- Bjornstad P, Dart A, Donaghue KC, Dost A, Feldman EL, Tan GS, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Microvascular and macrovascular complications in children and adolescents with diabetes. Pediatr Diabetes. 2022;23(8):1432-1450.
- National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. NICE guideline NG17 (recommandations 1.6, 1.11, 1.12.2 et 1.14.39).
- American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27-S49.
- République italienne. Legge 15 settembre 2023, n. 130 : Disposizioni concernenti la definizione di un programma diagnostico per l'individuazione del diabete di tipo 1 e della celiachia nella popolazione pediatrica. Gazzetta Ufficiale n. 226 du 27/09/2023.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1487 (anticorps anti-TPO), 1208 (TSH), 1828 (anti-transglutaminase IgA), 1577 (HbA1c) et 1576 (protéines glyquées).
- American Diabetes Association Professional Practice Committee. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
- Deutsche Diabetes Gesellschaft (DDG). S3-Leitlinie Therapie des Typ-1-Diabetes, 2. Auflage. AWMF-Registernummer 057-013, 2018 (validité indiquée : mai 2018 à mai 2023).
- American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
- Phelan H, Hanas R, Hofer SE, James S, Landry A, Lee W, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Sick day management in children and adolescents with diabetes. Pediatr Diabetes. 2022;23(7):912-925.